NAMS — NewAmsterdam Pharma Company
In 2026 Q2, 5 of the 140 tracked hedge funds reported a position in NewAmsterdam Pharma Company (NAMS), worth $174.59M combined. Over the quarter 2 opened or added, 1 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Duquesne | $104.05M | 2.40% | NO CHANGE |
| Polar Capital | $58.44M | 0.17% | -39.1% |
| Slate Path | $10.81M | 0.15% | NO CHANGE |
| Quadrature | $1.04M | 0.00% | NEW |
| Persistent | $246.85K | 0.08% | NEW |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.